Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Retained Earnings (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Retained Earnings for 4 consecutive years, with -$186.4 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 4888.42% to -$186.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$186.4 million through Dec 2025, down 4888.42% year-over-year, with the annual reading at -$178.3 million for FY2025, N/A changed from the prior year.
  • Retained Earnings for Q4 2025 was -$186.4 million at Neuphoria Therapeutics, up from -$188.3 million in the prior quarter.
  • The five-year high for Retained Earnings was $9.0 million in Q2 2022, with the low at -$188.3 million in Q3 2025.
  • Average Retained Earnings over 4 years is -$108.4 million, with a median of -$157.6 million recorded in 2023.
  • Peak annual rise in Retained Earnings hit 5.32% in 2025, while the deepest fall reached 4888.42% in 2025.
  • Over 4 years, Retained Earnings stood at $9.0 million in 2022, then tumbled by 1625.71% to -$136.9 million in 2023, then skyrocketed by 97.27% to -$3.7 million in 2024, then crashed by 4888.42% to -$186.4 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$186.4 million, -$188.3 million, and -$178.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.